-
1 Comment
Shanghai Medicilon Inc is currently in a long term uptrend where the price is trading 44.0% above its 200 day moving average.
From a valuation standpoint, the stock is 251.0% more expensive than other stocks from the Healthcare sector with a price to sales ratio of 33.8.
Shanghai Medicilon Inc's total revenue rose by 26.6% to $173M since the same quarter in the previous year.
Its net income has increased by 41.2% to $28M since the same quarter in the previous year.
Finally, its free cash flow grew by 704.9% to $36M since the same quarter in the previous year.
Based on the above factors, Shanghai Medicilon Inc gets an overall score of 4/5.
| ISIN | CNE100003NQ8 |
|---|---|
| Sector | Healthcare |
| Industry | Biotechnology |
| Exchange | SHG |
| CurrencyCode | CNY |
| PE Ratio | None |
|---|---|
| Market Cap | 4B |
| Beta | 0.79 |
| Target Price | None |
| Dividend Yield | None |
Shanghai Medicilon Inc., a drug discovery contract research organization, provides drug discovery and development services to pharmaceutical and biotechnology companies in China and internationally. It offers chemistry services, including medicinal, synthesis, and analytical chemistry services, as well as process development services; and drug formulation services, such as pre-formulation and analytical development services, as well as research on quality control and clinical trial material services. The company also provides biology services comprising recombinant protein, crystallization and structural, discovery biology, computational biology and molecular modeling, and kinase services, as well as prepackaged M9 selenomethionine growth media kits and packages for growing cell culture in IPTG-inducible bacterial expression systems. In addition, it offers pharmacology services, including cancer xenograft, metabolic disease, inflammation and immunological, neurological disorders, and other disease models; services in the areas of in vitro ADME and in vivo pharmacokinetics; and bioanalytical services, such as large and small molecule services. Further, the company provides preclinical services comprising preclinical pharmacokinetic and safety evaluation. Shanghai Medicilon Inc. was founded in 2004 and is headquartered in Shanghai, China.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for 688202.SHG using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025
